12479 results for
Refine Your Search
"Who We Are" Article node
Lorem ipsum odor amet, consectetuer adipiscing elit. Nec dignissim sem; parturient dui tortor litora convallis. Sociosqu curabitur auctor aliquet susc…
"Ways to Help" Article
Lorem ipsum odor amet, consectetuer adipiscing elit. Nec dignissim sem; parturient dui tortor litora convallis. Sociosqu curabitur auctor aliquet susc…
"Advocate" article
Lorem ipsum odor amet, consectetuer adipiscing elit. Nec dignissim sem; parturient dui tortor litora convallis. Sociosqu curabitur auctor aliquet susc…
"Research" Article
Lorem ipsum odor amet, consectetuer adipiscing elit. Nec dignissim sem; parturient dui tortor litora convallis. Sociosqu curabitur auctor aliquet susc…
"News" Article
Lorem ipsum odor amet, consectetuer adipiscing elit. Nec dignissim sem; parturient dui tortor litora convallis. Sociosqu curabitur auctor aliquet susc…
"Chemotherapy Drug Listing" Article
Lorem ipsum odor amet, consectetuer adipiscing elit. Nec dignissim sem; parturient dui tortor litora convallis. Sociosqu curabitur auctor aliquet susc…
Solu Therapeutics
Solu Therapeutics is a biotechnology company dedicated to developing therapeutics to eliminate cells in cancer, immunology and other therapeutic are…
A phase 1 study of STX-0712, a CCR2-CyTAC monocyte depletor, in patients with CMML
In December , LLS made an equity investment in Solu Therapeutics to "Support Preclinical and Clinical Development of in hematological malignancies, p…
Jean Koff
Dr. Jean Koff is an Associate Professor in the Department of Hematology and Medical Oncology and Director of the Lymphoma Program’s Translational Rese…
Paolo Caimi
Paolo Caimi is a physician and clinical investigator at the Cleveland Clinic, where he is also the Associate Bone Marrow Transplant Director for Cellu…
Paolo Caimi
Paolo Caimi is a physician and clinical investigator at the Cleveland Clinic, where he is also the Associate Bone Marrow Transplant Director for Cellu…
Genomic and epigenomic interactions of complex structural variants affecting outcome in multiple myeloma
Multiple myeloma is characterized by severe changes in chromosomes that result in gains or losses of genetic material. Several key events disrupt the …
Targeting aberrant epigenetic condensates in myeloid malignancies
Genetic changes of ASXL1 are very frequent in human blood cancers. We found that the altered forms of ASXL1 protein promote blood cancers through form…
Modeling LSC heterogeneity at unprecedented resolution in AML
Our goal is to perform molecular characterization of human leukemia stem cells (LSCs). We have developed an integrated set of techniques that will a…
Targeting Microenvironment Determinants in Peripheral T-cell Lymphoma
Peripheral lymphomas are highly aggressive blood cancer that have very poor survival rate, highlighting the need for new therapies to improve patient…